364 related articles for article (PubMed ID: 24080335)
41. Comparison of Botulinum Toxin Injections and Type 2 Thyroplasty for Adductor Spasmodic Dysphonia.
Sanuki T; Takemoto N
Laryngoscope; 2023 Dec; 133(12):3443-3448. PubMed ID: 37278482
[TBL] [Abstract][Full Text] [Related]
42. Refractory Dysphonia Due to Isolated Cricothyroid Muscle Dystonia.
Kraft S; Childes J; Hillel A; Schindler J
J Voice; 2016 Jul; 30(4):501-5. PubMed ID: 26239970
[TBL] [Abstract][Full Text] [Related]
43. Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia.
Stong BC; DelGaudio JM; Hapner ER; Johns MM
Arch Otolaryngol Head Neck Surg; 2005 Sep; 131(9):793-5. PubMed ID: 16172357
[TBL] [Abstract][Full Text] [Related]
44. Factors influencing long-term treatment response to botulinum toxin injection for spasmodic dysphonia.
Kang MS; Lee SJ; Choi HS; Lim JY
Clin Otolaryngol; 2021 Mar; 46(2):436-444. PubMed ID: 33260261
[TBL] [Abstract][Full Text] [Related]
45. Movement Disorders and Voice.
Snow G; Guardiani E
Otolaryngol Clin North Am; 2019 Aug; 52(4):759-767. PubMed ID: 31076164
[TBL] [Abstract][Full Text] [Related]
46. Common practices in botulinum toxin injection for spasmodic dysphonia treatment: A national survey.
Shoffel-Havakuk H; Rosow DE; Lava CX; Hapner ER; Johns MM
Laryngoscope; 2019 Jul; 129(7):1650-1656. PubMed ID: 30582627
[TBL] [Abstract][Full Text] [Related]
47. A single-centre retrospective review of unilateral and bilateral Dysport injections in adductor spasmodic dysphonia.
Elmiyeh B; Prasad VM; Upile T; Saunders N; Youl BD; Epstein R; Rubin JS
Logoped Phoniatr Vocol; 2010 Apr; 35(1):39-44. PubMed ID: 20350075
[TBL] [Abstract][Full Text] [Related]
48. The point-touch technique for botulinum toxin injection in adductor spasmodic dysphonia: quality of life assessment.
Morzaria S; Damrose EJ
J Laryngol Otol; 2011 Jul; 125(7):714-8. PubMed ID: 21524329
[TBL] [Abstract][Full Text] [Related]
49. Laryngeal dystonia gravidarum: sudden onset of adductor spasmodic dysphonia in pregnancy.
Ankola A; Sulica L; Murry T
Laryngoscope; 2013 Dec; 123(12):3127-30. PubMed ID: 23712421
[TBL] [Abstract][Full Text] [Related]
50. OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): Functional results and the role of dosage.
Marchese MR; D'Alatri L; Bentivoglio AR; Paludetti G
Toxicon; 2018 Dec; 155():38-42. PubMed ID: 30315835
[TBL] [Abstract][Full Text] [Related]
51. Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia.
Shoffel-Havakuk H; Marks KL; Morton M; Johns MM; Hapner ER
Laryngoscope; 2019 Feb; 129(2):448-453. PubMed ID: 30315575
[TBL] [Abstract][Full Text] [Related]
52. A comparison of the efficacy of unilateral versus bilateral botulinum toxin injections in the treatment of adductor spasmodic dysphonia.
Maloney AP; Morrison MD
J Otolaryngol; 1994 Jun; 23(3):160-4. PubMed ID: 8064952
[TBL] [Abstract][Full Text] [Related]
53. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
Troung DD; Rontal M; Rolnick M; Aronson AE; Mistura K
Laryngoscope; 1991 Jun; 101(6 Pt 1):630-4. PubMed ID: 2041443
[TBL] [Abstract][Full Text] [Related]
54. Socioeconomic Variables of Patients with Spasmodic Dysphonia: A Preliminary Study.
O'Connell Ferster AP; Sataloff RT; Shewokis PA; Hu A
J Voice; 2018 Jul; 32(4):479-483. PubMed ID: 28927659
[TBL] [Abstract][Full Text] [Related]
55. [Analysis of phonosurgical methods of treatment in spasmodic dysphonia].
Kosztyła-Hojna B; Berger G; Zdrojkowski M
Pol Merkur Lekarski; 2017 Feb; 42(248):90-92. PubMed ID: 28258685
[TBL] [Abstract][Full Text] [Related]
56. Pharyngeal Dystonia Mimicking Spasmodic Dysphonia.
Shi LL; Simpson CB; Hapner ER; Jinnah HA; Johns MM
J Voice; 2018 Mar; 32(2):234-238. PubMed ID: 28651822
[TBL] [Abstract][Full Text] [Related]
57. Value of Laryngeal Electromyography in Spasmodic Dysphonia Diagnosis and Therapy.
Yang Q; Xu W; Li Y; Cheng L
Ann Otol Rhinol Laryngol; 2015 Jul; 124(7):579-83. PubMed ID: 25673120
[TBL] [Abstract][Full Text] [Related]
58. Voice handicap index results for older patients with adductor spasmodic dysphonia.
Wingate JM; Ruddy BH; Lundy DS; Lehman J; Casiano R; Collins SP; Woodson GE; Sapienza C
J Voice; 2005 Mar; 19(1):124-31. PubMed ID: 15766857
[TBL] [Abstract][Full Text] [Related]
59. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
Hogikyan ND; Wodchis WP; Spak C; Kileny PR
J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
[TBL] [Abstract][Full Text] [Related]
60. [Botulinum toxin. A new therapeutic alternative in spastic dysphonia (laryngeal abductor dystonia)].
Loven JO; Brøndbo K; Ganes T
Tidsskr Nor Laegeforen; 1993 Mar; 113(7):841-3. PubMed ID: 8480289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
